| Mr Ben Jacob Varghese, PT | |
|
241 North Rd, Poughkeepsie, NY 12601-1154 | |
| (845) 483-5160 | |
| Not Available |
| Full Name | Mr Ben Jacob Varghese |
|---|---|
| Gender | Male |
| Speciality | Physical Therapist |
| Location | 241 North Rd, Poughkeepsie, New York |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790803112 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | 028010-1 (New York) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Ben Jacob Varghese, PT 90 Jackman Dr # A, Poughkeepsie, NY 12603-1245 Ph: (845) 337-4580 | Mr Ben Jacob Varghese, PT 241 North Rd, Poughkeepsie, NY 12601-1154 Ph: (845) 483-5160 |
News Archive
The mechanism by which 'polycomb' proteins critical for embyronic stem cell function and fate are targeted to DNA has been identified by UCL scientists.
Cancer diagnostics company Biomoda, Inc. has received a notice of allowance for a Canadian patent application for a method of using its proprietary porphyrin-based compound that binds to cancer cells and causes them to fluoresce under specific frequencies of light when viewed under a fluorescent microscope.
Research from Dartmouth Medical School, demonstrating how malaria parasites form mutations that make them stubbornly resistant to drug therapy, may hold the key to a new treatments for a disease that afflicts more than half a billion people worldwide.
PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported that patient enrollment and dosing in the Phase II trial of its long-acting version of human growth hormone (hGH-CTP) are proceeding according to plan, with study completion targeted for mid-year 2011.
Spectrum Pharmaceuticals today announced that it has submitted an investigational new drug (IND) application to the U.S. Food & Drug Administration for SPI-014 (previously referred to as RENAZORB), a second-generation lanthanum-based nanoparticle phosphate binding agent, that has the potential to treat hyperphosphatemia in patients with Stage 5 chronic kidney disease, or end-stage renal disease (ESRD).
› Verified 1 days ago
Dr. Mark Joao, DPT, CSCS Physical Therapist Medicare: Medicare Enrolled Practice Location: 301 Manchester Rd Ste 101, Poughkeepsie, NY 12603 Phone: 845-454-4137 | |
Kevin Paul Marquis, P.T. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 2 Austin Ct, Poughkeepsie, NY 12603 Phone: 845-471-3017 Fax: 845-471-3073 | |
Heather Ann Vicari, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 4 Hawthorne Ln, Poughkeepsie, NY 12603 Phone: 845-463-5661 | |
Mrs. Shiela Rubia Jabujab, PT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 100 Franklin St, Poughkeepsie, NY 12601 Phone: 845-454-4100 Fax: 845-454-4175 | |
Michele Ann Hyland, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 301 Manchester Rd Ste 101, Poughkeepsie, NY 12603 Phone: 845-545-4137 | |
Miss Margrit T Bunk, Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 241 North Road, St Fancis Hospital, Poughkeepsie, NY 12601 Phone: 845-431-8202 | |
Miss Jamie Lee Mills, MSPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 241 North Road, Poughkeepsie, NY 12601 Phone: 845-431-8803 |